The goal of this 1:1 randomized, multi-center, open-label phase Ib/II clinical trial is to
explore the efficacy of the add-on of the anti-glutamatergic drugs gabapentin, sulfasalazine
and memantine to standard chemoradiotherapy with temozolomide compared to chemoradiotherapy
alone in patients with newly diagnosed glioblastoma.